# Codiak BioSciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/codiak-biosciences

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.codiakbio.com
- Total disclosed funding: $169M
- Latest round: Series C (Nov 17, 2017)
- Investors on record: 11

## About

Codiak BioSciences, Inc. is a US-based biotechnology company focused on developing exosome-based therapeutics, utilizing its proprietary EngEx™ platform for targeted drug delivery in cancer treatment and other medical applications.Codiak BioSciences specializes in exosome-based therapeutics, seeking to innovate medical treatment solutions. Founded in 2015 and headquartered in Cambridge, US, the company has undergone a significant pivot to focus on engineered exosomes since inception. CEO Douglas Williams leads the firm, which has raised a total of USD 57.75 mn through multiple funding rounds, with the latest being a Private Placement/Follow on in February 2021. Since its founding, Codiak has completed 6 deals, the most recent occurring on February 11, 2021.Codiak BioSciences specializes in exosome-based therapeutics, leveraging its proprietary EngEx™ platform to develop and manufacture engineered exosomes for various medical applications. Their primary focus is on delivering targeted therapies for oncology and other diseases, enhancing treatment efficacy through exosome-mediated drug delivery. The clientele includes biopharmaceutical companies and research institutions across North America and Europe, who utilize these innovative therapies in clinical settings, particularly in responses to unmet medical needs in cancer treatment.In the most recent fiscal year 2021, Codiak BioSciences reported a revenue of USD 22.94 mn, while experiencing an EBITDA loss of USD 64.21 mn. Revenue generation primarily arises from partnerships and collaborations with pharmaceutical companies, along with potential licensing agreements for proprietary technologies and products.Codiak BioSciences plans to utilize recent funding from the February 2021 Private Placement, totaling USD 57.75 mn, to advance initial product candidates into clinical trials and further develop its exosome therapeutic platform. There are initiatives to expand into specific markets in the United States and select European regions where there is a demand for advanced therapeutic solutions. The company is also focused on launching new engineered exosome products aimed at addressing unmet medical needs in oncology within the upcoming years.

## Funding rounds

- Series C, Nov 17, 2017, $77M — ARCH Venture Partners, Flagship Pioneering, Alaska Permanent Fund Corporation, Alexandria Venture Investments, Qatar Investment Authority, Fidelity Investments, Yukon Partners, Casdin Capital, EcoR1 Capital, Boxer Capital, Sirona Capital
- Series B, Jan 26, 2016, $61M — ARCH Venture Partners, Flagship Pioneering, Alaska Permanent Fund Corporation, Alexandria Venture Investments, Fidelity Investments
- Series A, Nov 12, 2015, $31M — ARCH Venture Partners, Flagship Pioneering, Alaska Permanent Fund Corporation, Alexandria Venture Investments, Fidelity Investments

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B, Series C
- Alaska Permanent Fund Corporation — Series A, Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B, Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series A, Series B, Series C
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series C
- Yukon Partners (https://capitalatlas.ai/funds/yukon-partners) — Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series C
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series C
- Sirona Capital (https://capitalatlas.ai/funds/sirona-capital) — Series C